Table 2 Treatment efficacy following Ld-IL2 treatment in responders and non-responders

SELENA-SLEDAI, median (range)

 Responders

11 (8–16)

4 (2–6)

< 0.001

 Non-responders

9 (6–14)

6 (4–9)

0.191

Rash, n (%)

 Responders

43 (31.6)

7 (5.1)

< 0.001

 Non-responders

39 (21.9)

12 (6.7)

< 0.001

Leukopenia, n (%)

 Responders

25 (18.4)

10 (7.4)

0.034

 Non-responders

33 (18.5)

18 (10.1)

0.076

Thrombocytopenia, n (%)

 Responders

31 (22.8)

10 (7.4)

0.003

 Non-responders

32 (18.0)

18 (10.1)

0.100

WBC, × 109/L, median (range)

 Responders

6.13 (4.38–8.35)

6.20 (4.66–9.28)

0.285

 Non-responders

5.50 (4.20–7.82)

5.92 (4.37–7.49)

0.399

Platelet, × 1012/L, median (range)

 Responders

197 (133, 251)

216 (177–286)

0.005

 Non-responders

199 (153, 265)

217 (180–268)

0.069

IgA, g/L, median (range)

 Responders

2.23 (1.37, 2.87)

2.05 (1.38–2.93)

0.860

 Non-responders

2.52 (1.68, 3.19)

2.40 (1.56–3.28)

0.609

IgG, g/L, median (range)

 Responders

11.60 (8.20, 15.00)

10.96 (9.13–13.04)

0.387

 Non-responders

13.25 (9.60, 16.95)

11.41 (8.53–14.88)

0.045

IgM, g/L, median (range)

 Responders

0.87 (0.52, 1.33)

0.82 (0.45–1.23)

0.419

 Non-responders

0.86 (0.57, 1.26)

0.83 (0.56–1.21)

0.465

C3, g/L, median (range)

 Responders

0.71 (0.57, 0.91)

0.89 (0.76–1.05)

< 0.001

 Non-responders

0.81 (0.63, 0.96)

0.83 (0.70–0.98)

0.089

C4, g/L, median (range)

 Responders

0.16 (0.12, 0.21)

0.22 (0.15–0.27)

< 0.001

 Non-responders

0.17 (0.12, 0.22)

0.18 (0.14–0.24)

0.106

Anti-dsDNA, IU/mL, median (range)

 Responders

28.80 (10.15, 56.00)

16.35 (9.20–35.38)

0.058

 Non-responders

18.00 (8.50–56.80)

20.70 (9.35–47.25)

0.479

AnuA, IU/mL, median (range)

 Responders

16.5 (5.04, 73.66)

10.37 (3.45–26.04)

0.230

 Non-responders

9.67 (1.20, 28.71)

7.33 (2.14–21.21)

0.910

UrinePRO, g/24 h, median (range)

 Responders

0.68 (0.24, 2.20)

0.38 (0.20–1.68)

0.028

 Non-responders

0.26 (0.14–1.34)

0.60 (0.19–1.49)

0.194